BioPharmX

79 articles about BioPharmX

• BioPharmX Completes 1-for-25 Reverse Stock Split

  4/26/2019

  BioPharmX Corporation announces the completion of the reverse stock split previously announced on April 15, 2019 to regain compliance with certain NYSE American continued listing standards related to the low price per share of the Company's common stock.

• BioPharmX Announces Reverse Stock Split

  4/15/2019

  BioPharmX Corporation announced that its Board of Directors has approved a reverse stock split of its common stock at a ratio of 1-for-25.

• BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results

  3/14/2019

  BioPharmX Corporation, a specialty pharmaceutical company focused on developing innovative medical dermatology products, reports financial results for the quarter and year ended January 31, 2019.

• BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea

  3/4/2019

  Company anticipates announcing topline efficacy and safety results in July 2019

• 

  BioSpace Movers and Shakers - Oct. 22

  10/22/2018

  Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes.

• BioPharmX Cancels Presentation at Oppenheimer's 28th Annual Healthcare Conference Due to Severe Weather

  3/21/2018

  BioPharmX Corporation announces that it has cancelled its presentation at Oppenheimer's 28th Annual Healthcare Conference in New York tomorrow, due to the winter storm warnings forecasted for the region.

• U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug Compositions

  3/20/2018

  Patent protects a new category of innovative drug delivery systems New patent is the second granted to BioPharmX in 3 weeks

• BioPharmX Reports Third Quarter 2018 Financial Results

  12/8/2017

  Total operating expenses for the third quarter of 2018 were $3.7M, compared with total operating expenses of $4.2M in the prior fiscal year's third quarter.

• BioPharmX Demonstrates Topical Minocycline Gel May Exhibit Relevant Antimicrobial and Anti-Inflammatory Properties for the Treatment of Acne at ASCB 2017

  12/4/2017

  Study findings show that minocycline has anti-inflammatory activities in in vitro and animal models.

• BioPharmX Announces Pricing of Public Offering

  11/21/2017

  The Series A common warrants will be exercisable immediately at an exercise price of$$0.20 per share and will expire five years from the date of issuance.

• BioPharmX Receives Concurrence From FDA on Phase III Acne Study Plans

  11/8/2017

  The company has incorporated feedback from the FDA on key elements of its phase III acne program.

• BioPharmX Collaborates With Wellman Center For Photomedicine To Develop Pioneering, Cost-Effective Technique To Visualize Drug Delivery

  10/11/2017

• BioPharmX Second Quarter 2018 Financial Results

  9/13/2017

• BioPharmX Announces Preliminary Data From Rosacea Feasibility Study

  9/12/2017

• BioPharmX Release: Summer AAD Panel To Discuss BPX-01 For Acne And Rosacea

  7/27/2017

• BioPharmX To Present Phase IIb Clinical Trial Acne Data At Alabama Dermatology Society Summer Symposium

  6/22/2017

• BioPharmX Reports First Quarter 2018 Financial Results

  6/14/2017

• BioPharmX To Report First Quarter Financial Results

  6/7/2017

• BioPharmX Advances BPX-01 2% Upon Achieving Statistical Significance For Primary Endpoint

  6/1/2017

• BioPharmX Reports Positive Topline Results Of BPX-01 Topical Minocycline For Acne

  5/4/2017